Be the first person to write a business review for CeMines Biologics, LLC

Corgenix Medical Corporation company was founded in 1985 and is headquartered in Broomfield, Colorado. Corgenix Medical Corporation, together with its subsidiaries, engages in the research, development, manufacture, and marketing of in vitro diagnostic products for use in disease detection and prevention in the United States and internationally. The company offers autoimmune disease products that are used for the diagnosis and monitoring of autoimmune diseases, including RA, SLE, mixed connective tissue diseases, Sjogren’s Syndrome, Dermatopolymyositis, and Scleroderma; and antiphospholipid antibody testing products, which are used in the diagnosis of clotting and bleeding disorders, including von Willebrand's disease. It also provides AspirinWorks, a urine test kit that measures an individual's response to aspirin dosage and allows physicians to adjust the dosage or recommend alternative therapy; and liver disease products, which include hyaluronic acid, a component of the matrix of connective tissues found in synovial fluid of the joints where it acts as a lubricant and for water retention. The company sells its products to hospitals, clinical testing laboratories, universities, biotechnology and pharmaceutical companies, and research institutions. It markets its products through a network of sales representatives, distributors, and private label agreements.

Dako makes disease diagnosis a little more clear-cut. A leader in the area of pathology testing, Dako makes instrumentation systems, reagents, and software used by pathology laboratories to analyze human tissues for the presence of cancer. Its Automated Link line of pathology instruments include staining and visualization systems, chemical and antibody reagents, and Dako Link workflow management software. The company also makes reagents used in flow cytometry testing (which analyzes the cells in blood) and in clinical immunochemistry (which measures proteins in body fluids). The company was acquired by private equity fund EQT in 2007 and subsequently divested its flow cytometry instrumentation business.

diaDexus, Inc. was founded in 1997 and is based in South San Francisco, California. diaDexus, Inc., a biotechnology company, engages in the discovery, development, and commercialization of in vitro diagnostic products to address the medical needs in the cardiovascular field. The company develops The PLAC Test, a blood test to aid in assessing risk for coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis. Its product measures lipoprotein-associated phospholipase A2 (Lp-PLA2), which is a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. The company’s PLAC Test is available as an ELISA assay that runs on an automated micropate system, as well as in the form of immunotarbidimetric technology that runs on common clinical chemistry analyzers used in clinical reference laboratories, hospitals, and physician office laboratories.

DiagnoCure Inc. company was founded in 1994 and is headquartered in Quebec City, Canada. DiagnoCure, Inc., a life sciences company, engages in the research, development, production, and commercialization of diagnostic tests for the detection and management of cancers in Canada. It focuses on colon, prostate, breast, and lung cancers. The company provides ImmunoCyt /uCyt+, a tool for the diagnosis and monitoring of bladder cancer; uPM3, a noninvasive test for the detection of prostate cancer; and molecular diagnostic tests for lung cancer. It also offers Previstage GCC colorectal cancer staging test for the management of colorectal cancer. The company holds worldwide diagnostic and therapeutic rights for the use of the PCA3 technology in prostate cancer diagnosis. DiagnoCure has a strategic alliance with Gen-Probe Incorporated for the development and commercialization of diagnostic products using the DiagnoCure PCA3 gene technology for prostate cancer.

Epigenomics AG is a Germany-based company engaged in the molecular diagnostics sector. It divides its products into two areas: solutions for early diagnosis of cancer and products for special diagnosis of cancer. Epigenomics AG produces and develops tests that help in the diagnosis of the colorectal, prostate and lung cancer. The Company also offers services in the field of identification and development of methylated deoxyribonucleic acid (DNA) biomarkers. Industry partners and the medical and life science communities can access the Company’s portfolio of filed patent families covering DNA methylation technologies and biomarkers, as well as its DNA methylation expertise through research products, biomarker services, in vitro diagnostics (IVD) development collaborations and licensing. It develops its solutions together with its commercial partners, Abbott Molecular Inc and Quest Diagnostics Inc. The Company has a subsidiary in the United States, Epigenomics, Inc.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.